GlassScriptPhysician profile
Olga Benitez
NPI 1275741209
$951.82
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $67.41 · 2021: $111 · 2022: $361 · 2023: $61.95 · 2024: $42.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $104.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.71 | 2021-2023 | Trulance, Xifaxan |
| Qiagen, LLC | $162.02 | 2019 | |
| Glaxosmithkline, LLC. | $123.41 | 2022 | |
| Amarin Pharma, INC. | $81.12 | 2019-2023 | |
| Allergan, INC. | $48.40 | 2019-2020 | |
| Abiomed | $42.31 | 2024 | Impella |
| Horizon Therapeutics Plc | $42.07 | 2020-2022 | |
| Astellas Pharma US INC | $33.53 | 2022 | |
| Lilly USA, LLC | $31.42 | 2019-2022 | |
| Novo Nordisk INC | $29.46 | 2020-2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $28.36 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.95 | 2023 | Nuedexta |
| Janssen Pharmaceuticals, INC | $14.81 | 2019 | |
| Pfizer INC. | $14.75 | 2019 | |
| Scynexis, INC. | $14.59 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.39 | 2019 | |
| Amgen INC. | $13.30 | 2019 | |
| Lupin INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Benitez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.